Chemomab Therapeutics Business Summary

Chemomab Therapeutics Ltd. (CMMB) is a clinical-stage biotechnology company that operates through a research and development business model, currently generating zero revenue as it advances its proprietary pipeline toward future licensing, strategic collaborations, or commercialization. The company’s operations are concentrated in a single segment: the discovery and development of monoclonal antibodies for fibro-inflammatory diseases with high unmet needs. Its lead candidate, nebokitug (CM-101), is a first-in-class dual-action antibody that neutralizes the CCL24 protein to disrupt the cycle of inflammation and fibrosis. Nebokitug has successfully completed a Phase 2 trial for primary sclerosing cholangitis (PSC) and is currently in Phase 2 for systemic sclerosis (SSc). Chemomab competes in the specialized fibrosis and rare disease markets against direct peers such as Telomir Pharmaceuticals, Liminatus Pharma, Talphera, and BioRestorative Therapies. As a small-cap clinical player, Chemomab occupies a high-potential niche, having recently secured alignment with the FDA and EMA for a streamlined, single Phase 3 registration trial pathway for PSC. The leadership team is anchored by Co-founder, CEO, and CSO Adi Mor, PhD, an immunology specialist from Tel Aviv University who has led the company’s growth from discovery to Phase 2 clinical trials. She is supported by CFO Sigal Fattal, who brings over 20 years of experience in managing IPOs and M&A transactions at firms like Evogene and BiomX, and Interim Chief Medical Officer David M. Weiner, MD, a 30-year industry veteran with prior executive roles at Lumos Pharma and aTyr Pharma. The executive team also includes Chief Development Officer Jack Lawler, who previously oversaw the company's successful Phase 2 SPRING trial. Strategic oversight is provided by Board Chairman Nissim Darvish, MD, PhD, a General Partner at MeOhr Ventures and former Venture Partner at OrbiMed Israel. Notable institutional investors include Sphera Funds Management, OrbiMed Advisors, and Yelin Lapidot Holdings, which maintain significant positions in the company as it prepares for its pivotal Phase 3 program.